Crossroads in GDNF therapy for Parkinson's disease | Zendy

Sherer Todd B. | Zendy; Fiske Brian K. | Zendy; Svendsen Clive N. | Zendy; Lang Anthony E. | Zendy; Langston J. William | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Crossroads in GDNF therapy for Parkinson's disease

Author(s) -

Sherer Todd B.,

Fiske Brian K.,

Svendsen Clive N.,

Lang Anthony E.,

Langston J. William

Publication year - 2006

Publication title -

movement disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.352

H-Index - 198

eISSN - 1531-8257

pISSN - 0885-3185

DOI - 10.1002/mds.20861

Subject(s) - glial cell line derived neurotrophic factor , parkinson's disease , medicine , physical medicine and rehabilitation , neuroscience , psychology , disease , neurotrophic factors , receptor

The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial‐derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. © 2006 Movement Disorder Society

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research